OakChart

CAMP4 Therapeutics Corp

CAMPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

4.20-0.13 (-3.00%)
2026-11-12 05:28 CET
Market cap
263.57 USD m
Revenue, TTM
5.32 USD m
Net income, TTM
-121.10 USD m
Free cash flow, TTM
-26.41 USD m
EPS diluted, TTM
-2.04
P/E
-
Compare

Price

CAMP against its 20, 50 and 200-day averages
2050200miss
3.004.005.006.001.7M3.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CAMPclose 4.2020-day 3.6850-day 3.87200-day 4.204.2052w low

45.8% under the 52-week high of 7.75 on 9 Mar 2026. 52-week low 2.90 on 21 Nov 2025. Last 15 sessions, 55.8% high to low

Volume 0.37× normal · the line is the 50-bar volume average

Profile

CAMP
52-week range, 27% of the way up
2.907.75

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

IndexRUT
Employees48
IPOOct 11, 2024
Beta0.23
ATR, 14d0.36
Rel volume0.37
Short float10.56%
Insider own50.81%
Inst own54.07%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap263.57M
Enterprise Value144.77M
Income-121.10M
Sales5.32M
Book/sh1.71
Cash/sh2.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees48
IPOOct 11, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S49.54
P/B2.46
P/C2.10
P/FCF-
EV/EBITDA-
EV/Sales27.21
Quick Ratio6.42
Current Ratio6.42
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.04
EPS next Y-0.75
EPS next Q-0.18
EPS this Y50.27%
EPS next Y42.81%
EPS next 5Y34.18%
EPS past 3/5Y-5.31% -
Sales past 3/5Y- -
EPS Y/Y TTM16.95%
Sales Y/Y TTM39.93%
EPS Q/Q33.74%
Sales Q/Q138.87%
EarningsNov 05 AMC
EPS/Sales Surpr.-90.92% 10.62%

Ownership

Insider Own50.81%
Insider Trans-1.69%
Inst Own54.07%
Inst Trans0.79%
ROA-109.89%
ROE-146.12%
ROIC-108.20%
Gross Margin64.00%
Oper. Margin-1001.05%
Profit Margin-2276.33%
SMA2014.11%
SMA508.56%
SMA200-0.01%
Trades-

Technical

Shs Outstand62.75M
Shs Float30.87M
Short Float10.56%
Short Ratio12.65
Short Interest3.26M
52W High7.75 -45.81%
52W Low2.90 44.83%
Volatility12.16% 9.16%
ATR (14)0.36
RSI (14)57.54
Beta0.23
Rel Volume0.37
Avg Volume257.68K
Volume95,229

Performance

Perf Week12.30%
Perf Month22.45%
Perf Quarter-6.67%
Perf Half Y-6.67%
Perf YTD-31.48%
Perf Year1.69%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price9.90
Prev Close4.33
Price4.20
Change %-3.00%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 23, 2026InitiatedRRaymond JamesStrong Buy$10+138.1%
Oct 15, 2026InitiatedNNeedhamBuy$8+90.5%
Oct 05, 2026InitiatedOOppenheimerOutperform$15+257.1%
Jun 16, 2026UpgradeJJP MorganNeutral → Overweight$9+114.3%
Jun 10, 2026InitiatedCChardan Capital MarketsBuy$6.50+54.8%
Apr 14, 2026InitiatedRRodman & RenshawBuy$7+66.7%
Oct 02, 2025InitiatedCCantor FitzgeraldOverweight$7+66.7%
Sep 16, 2025DowngradeJJP MorganOverweight → Neutral
May 27, 2025InitiatedWWedbushOutperform$8+90.5%
Nov 05, 2024InitiatedWWilliam BlairOutperform

Peers

Mkt cap
TickerCompanyMkt cap
STOKStoke Therapeutics Inc1.82B
IONSIonis Pharmaceuticals Inc4.72B
WVEWave Life Sciences Inc674.52M
KRROKorro Bio Inc197.78M
ADRXADARx Pharmaceuticals Inc1.47B
PRQRProQR Therapeutics N.V177.81M
ARWRArrowhead Pharmaceuticals Inc6.97B
SLNSilence Therapeutics Plc ADR1.23B
RAREUltragenyx Pharmaceutical Inc1.70B
BNTCBenitec Biopharma Inc330.41M

Insider trading

12 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gold KellyChief Financial OfficerAug 31 '26Buy3.9610,00039,60010,000Sep 02 07:50 PM
Schwab Andrew J.DirectorAug 27 '26Sale4.04400,0001,616,0002,033,270Aug 31 05:05 PM
Schwab Andrew J.DirectorAug 24 '26Sale4.5010452,433,270Aug 26 04:57 PM
Schwab Andrew J.DirectorAug 20 '26Sale4.54114,700520,7382,465,298Aug 21 04:59 PM
Schwab Andrew J.DirectorAug 19 '26Sale4.7645,147214,9002,579,998Aug 21 04:59 PM
Schwab Andrew J.DirectorAug 21 '26Sale4.5032,018144,0812,433,280Aug 21 04:59 PM
Tardiff DanielChief Scientific OfficerAug 19 '26Sale4.761,7388,2730Aug 19 08:46 PM
Daniel TardiffaffiliateAug 19 '26Proposed Sale4.761,7388,276Aug 19 10:23 AM
Young Richard ADirectorAug 03 '26Buy1.6516,37827,024186,388Aug 05 05:09 PM
Maricich YuriChief Medical OfficerAug 03 '26Buy1.656,55110,80912,611Aug 05 05:08 PM
Gold KellyChief Financial OfficerAug 03 '26Buy1.656,55110,80974,428Aug 05 05:08 PM
Mandel-Brehm JoshChief Executive OfficerAug 03 '26Buy1.656,55110,809284,968Aug 05 05:07 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 102
  • CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +9.14%
  • CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union (GlobeNewswire) +13.71%
  • CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference (GlobeNewswire)
  • CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder (GlobeNewswire)
  • CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 (GlobeNewswire)
  • CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +20.89%
  • CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement (GlobeNewswire)
  • CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder (GlobeNewswire) +8.23%
  • CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.51%
  • CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder (GlobeNewswire)
  • CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +6.90%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.370-0.194-0.3691.901.7210
2026Q22026-08-13-0.580-0.211-0.5791.781.627
2026Q12026-05-07-0.320-0.210-0.3171.301.125
2025Q42026-03-05-0.860-0.473-0.7760.330.486
2025Q32025-11-06-0.550-0.478-0.5540.800.436
2025Q22025-08-14-0.620-0.673-0.6241.420.575
2025Q12025-05-13-0.620-0.694-0.6170.870.214
2024Q42025-03-27-0.670-0.863-0.6590.650.684
2024Q32024-11-21-24.190-1.073-0.6690.000.254
2024Q22024-08-28-4.690--0.6450.00--
2023Q32024-01-09-3.3490.000-0.58053.6356.202
2023Q22023-10-05-0.0230.030-0.11061.7170.354
2023Q12023-07-10-0.0270.040-0.11070.8975.664
2022Q42023-04-270.0600.016-0.22078.5178.655
2022Q32022-12-200.0000.002-0.13078.8975.295
2022Q22022-09-22-0.020-0.028-0.21072.8369.276

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY25.99025.23111.960363.8365.97
2019FY10.1209.989-54.280366.11364.86
2020FY4.6312.859-37.720308.59335.33
2021FY1.8400.767-18.170295.84295.88
2022FY-1.840-2.392-2.266294.95295.08
2024FY-11.040-8.330-2.5710.650.77
2025FY-2.650-2.125-2.6303.503.55
2026FY--1.318--6.58
2027FY--0.754--6.16
2028FY--0.756--3.60
2029FY--0.733--2.64
2030FY--0.673--15.93

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-069322.000.003.63
2026Q4S2026-10-289101.720.003.60
2026Q4S2026-10-219511.720.003.60
2026Q4S2026-10-138511.930.003.60
2026Q4S2026-10-027512.110.003.60
2026Q4S2026-09-286512.461.003.60
2026Q4S2026-09-256512.451.003.60
2026Q4S2026-09-236512.461.003.63
2026Q4S2026-08-147512.110.003.63
2026Q4S2026-07-277001.750.003.08
2026Q4S2026-07-227101.750.003.08
2026Q4S2026-06-247311.750.003.08
2026Q4S2026-06-157311.750.003.08
2026Q4S2026-06-096312.040.753.08

Estimate history

EPS, annual-2.266-2.527-2.571-2.647-2.0382
Period2022202320242025TTM
EPS, quarterly-0.669-0.659-0.617-0.624-0.554-0.776-0.317-0.579-0.367
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00.350.6523.4985.32
Period2022202320242025TTM
Sales, quarterly00.6520.8581.4970.7950.3481.2941.7791.899
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual19.50519.50520.14551.90362.754
Period2022202320242025MRQ
Shares, quarterly20.16120.14520.15720.16146.8851.90351.92651.92762.754
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue5.323.500.650.350.00
Cost of Goods Sold Incl. D&A1.921.641.701.820.95
Gross Profit3.401.86-1.04-1.47-0.95
Selling, General and Administrative Excl. Other56.6653.9252.0450.4144.05
Research and Development38.8536.5637.1238.7933.82
Other Operating Expense0.000.000.000.000.00
Operating Income-53.26-52.06-53.09-51.88-45.00
Interest Expense0.000.00---
Unusual Expense70.9630.320.000.000.00
Net Income Before Taxes-121.10-80.40-51.79-49.29-44.19
Income Taxes0.000.000.000.000.00
Consolidated Net Income-121.10-80.40-51.79-49.29-44.19
Net Income From Continuing Operations-121.10-80.40-51.79-49.29-44.19
Net Income-121.10-80.40-51.79-49.29-44.19
EPS (Recurring)-0.90-1.95-2.57-2.53-2.27
EPS (Basic, Before Extraordinaries)-2.04-2.65-2.57-2.53-2.27
EPS (Diluted)-2.04-2.65-2.57-2.53-2.27
EBITDA-51.34-50.42-51.39-50.05-44.05
Non-Operating Income (Expense)3.121.981.302.590.81
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense6.584.004.032.911.38
Price To Sales Ratio59.9553.24161.28--
Gross Margin64.0053.14-160.12-421.14-
Operating Margin-1,001.05-1,488.31-8,142.33-14,822.57-
Net Margin-2,276.33-2,298.54-7,943.40-14,083.14-
Shares Outstanding62.7551.9020.1519.5119.51
Market Capitalization263.57263.57105.24109.07-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.901.781.290.350.801.500.860.65
Cost of Goods Sold Incl. D&A0.520.500.520.370.420.430.420.42
Gross Profit1.381.280.77-0.020.381.070.440.23
Selling, General and Administrative Excl. Other15.4014.6613.8512.7513.5414.1013.5414.27
Research and Development10.9110.329.647.998.949.919.729.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.03-13.38-13.07-12.78-13.16-13.03-13.10-14.03
Interest Expense0.000.000.000.00----
Unusual Expense15.8120.936.1928.032.290.000.000.00
Net Income Before Taxes-28.96-33.53-18.33-40.28-15.10-12.59-12.43-13.28
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-28.96-33.53-18.33-40.28-15.10-12.59-12.43-13.28
Net Income From Continuing Operations-28.96-33.53-18.33-40.28-15.10-12.59-12.43-13.28
Net Income-28.96-33.53-18.33-40.28-15.10-12.59-12.43-13.28
EPS (Recurring)-0.23-0.33-0.24-0.40-0.49-0.62-0.62-0.66
EPS (Basic, Before Extraordinaries)-0.37-0.58-0.32-0.78-0.55-0.62-0.62-0.66
EPS (Diluted)-0.37-0.58-0.32-0.78-0.55-0.62-0.62-0.66
EBITDA-13.51-12.88-12.55-12.40-12.74-12.60-12.68-13.62
Non-Operating Income (Expense)0.890.780.930.520.350.440.670.76
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.021.931.471.150.981.000.860.80
Price To Sales Ratio59.9560.0564.9390.9621.529.7253.39161.28
Gross Margin72.4671.8959.81-6.9047.6771.2850.9335.89
Operating Margin-738.76-752.11-1,010.12-3,671.26-1,654.97-870.27-1,526.81-2,152.45
Net Margin-1,524.80-1,884.77-1,416.62-11,575.86-1,899.25-840.81-1,449.07-2,036.66
Shares Outstanding62.7551.9351.9351.9046.8820.1620.1620.15
Market Capitalization263.57226.92228.96318.0360.4829.2380.64105.24

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments110.8664.0438.3883.19
Short Term Receivables0.150.110.440.68
Inventories0.000.000.000.00
Other Current Assets3.082.241.190.54
Total Current Assets114.0966.3840.0184.41
Net Property, Plant & Equipment2.7410.3013.3116.79
Total Investments and Advances0.891.621.621.35
Intangible Assets-0.000.000.00
Other Assets0.080.000.000.00
Total Assets117.8178.3154.95102.55
Short Term Debt Incl. Current Port. of LT Debt0.293.173.462.37
Accounts Payable0.181.211.042.15
Other Current Liabilities15.055.223.303.42
Total Current Liabilities15.519.607.817.95
Long Term Debt1.695.568.7210.03
Provision for Risks Charges0.000.000.000.00
Other Liabilities52.900.000.000.00
Total Liabilities70.1015.1616.5317.97
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00162.15162.15
Common Equity47.7063.14-123.73-77.53
Total Shareholders Equity47.7063.1438.4284.62
Accumulated Minority Interest0.000.000.000.00
Total Equity47.7063.1438.4284.62
Total Liabilities & Stockholders Equity117.8178.3154.95102.59
Book Value Per Share0.923.13-6.34-3.97
Tangible Book Value Per Share0.923.13-6.34-3.97
Full-Time Employees485558-
Price to Book Ratio2.46-0.66-0.69-
Return on Assets-82.00-77.73-62.59-
Return on Equity-145.07-101.99-80.13-
Return on Invested Capital-162.79-75.38-104.57-46.69
Quick Ratio7.356.925.1310.62
Current Ratio7.356.925.1310.62

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-121.10-80.40-51.79-49.29-44.19
Depreciation1.931.641.701.680.88
Other Funds (Non Cash)78.4036.201.884.733.07
Funds from Operations-40.77-42.56-48.21-42.89-40.25
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital15.2413.01-1.33-1.271.70
Cash from Operating Activities-25.54-29.55-49.54-44.16-38.54
Capital Expenditures-0.87-0.28-0.44-0.68-4.03
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.040.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00
Purchase of Investments0.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-0.87-0.24-0.44-0.68-4.03
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock75.6961.1776.470.18100.25
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock75.6961.1776.470.18100.25
Proceedsfrom Stock Options72.9957.5276.350.00100.19
Issuance or Reduction of Debt, Net-0.02-0.21-0.820.12-0.09
Change in Long Term Debt-0.02-0.21-0.820.12-0.09
Issuance of Long Term Debt0.000.000.000.710.00
Reduction of Long Term Debt-0.02-0.21-0.82-0.59-0.09
Net Financing Active Other Cash Flow0.0014.930.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities75.6775.8975.640.30100.16
Net Change in Cash49.2746.0925.66-44.5357.59
Free Cash Flow-26.41-29.83-49.98-44.83-42.57
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments125.2587.1399.94110.8675.2539.05
Short Term Receivables0.220.220.000.150.000.11
Inventories0.000.000.000.000.000.00
Other Current Assets2.072.682.263.082.451.93
Total Current Assets127.5490.03102.20114.0977.7141.09
Net Property, Plant & Equipment5.522.442.292.747.068.56
Total Investments and Advances0.890.890.890.891.621.62
Intangible Assets----0.000.00
Other Assets0.060.070.080.080.000.00
Total Assets134.0193.43105.46117.8186.3951.27
Short Term Debt Incl. Current Port. of LT Debt1.620.800.380.293.253.27
Accounts Payable0.761.090.860.180.581.20
Other Current Liabilities17.4817.2515.3815.054.072.87
Total Current Liabilities19.8619.1416.6215.517.907.33
Long Term Debt4.831.571.741.693.093.95
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.2373.4156.1952.9016.730.00
Total Liabilities26.9294.1274.5670.1027.7311.29
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity107.09-0.6930.9047.7058.6739.99
Total Shareholders Equity107.09-0.6930.9047.7058.6739.99
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity107.09-0.6930.9047.7058.6739.99
Total Liabilities & Stockholders Equity134.0193.43105.46117.8186.3951.27
Book Value Per Share1.71-0.010.600.921.251.98
Tangible Book Value Per Share1.71-0.010.600.921.251.98
Full-Time Employees---48--
Price to Book Ratio2.467.344.804.901.510.57
Return on Assets-109.89-148.23-102.60-82.00-99.11-127.51
Return on Equity-146.12-545.85-209.28-145.07-172.70-188.23
Return on Invested Capital-25.87-3,823.26-56.16-81.56-24.45-28.65
Quick Ratio6.424.706.157.359.835.60
Current Ratio6.424.706.157.359.835.60

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-28.96-33.53-18.33-40.28-15.10-12.59
Depreciation0.520.520.520.370.420.43
Other Funds (Non Cash)18.1523.017.7029.543.831.39
Funds from Operations-10.28-10.00-10.12-10.38-10.85-10.77
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.12-2.68-0.8616.67-0.370.43
Cash from Operating Activities-8.16-12.69-10.986.29-11.22-10.34
Capital Expenditures-0.74-0.130.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.040.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.74-0.130.000.000.040.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock47.030.000.0628.6032.560.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock47.030.000.0628.6032.560.00
Proceedsfrom Stock Options15.470.000.0057.520.000.00
Issuance or Reduction of Debt, Net0.000.000.00-0.02-0.110.07
Change in Long Term Debt0.000.000.00-0.02-0.110.07
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.02-0.110.07
Net Financing Active Other Cash Flow0.000.000.000.0014.930.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities47.030.000.0628.5947.380.07
Net Change in Cash38.12-12.81-10.9234.8836.20-10.27
Free Cash Flow-8.90-12.81-10.986.29-11.22-10.34

Revenue breakdown

Pharmaceutical Preparations2024: 652.00K 2025: 3.50M
United States2024: 652.00K 2025: 3.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.56%3.3M30.9M262.10K
2026-10-1511.18%3.5M30.9M269.77K
2026-09-304.46%1.5M32.8M241.03K
2026-09-153.03%1.0M32.8M285.04K
2026-08-313.62%1.2M32.8M250.63K
2026-08-143.65%1.3M35.0M213.86K
2026-07-315.59%1.5M26.5M190.37K
2026-07-155.44%1.4M26.5M171.31K
2026-06-304.94%1.3M26.5M154.81K
2026-06-151.50%0.4M26.5M86.69K
2026-05-291.29%0.3M26.5M190.64K
2026-05-151.22%0.3M26.5M187.55K
2026-04-301.86%0.5M24.2M183.32K
2026-04-152.20%0.5M21.3M190.23K
2026-03-312.01%0.4M20.6M197.17K
2026-03-132.35%0.5M20.6M250.73K
2026-02-272.51%0.5M20.6M153.78K
2026-02-132.80%0.6M20.5M159.98K
2026-01-302.57%0.5M20.9M166.55K
2026-01-152.30%0.5M20.9M162.92K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05SCHEDULE 13G/ASEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-31SCHEDULE 13D/ASEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19SCHEDULE 13D/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-12EFFECTEffectiveness filing by commission orderSEC
2026-08-12424B3SEC
2026-08-10SCHEDULE 13GSEC
2026-08-06S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-05SCHEDULE 13D/ASEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0899.05K52.50M6
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Jupiter Topco LLC12.15%
5AM Venture Management, LLC11.30%
Vivo Capital, LLC8.18%
FMR LLC7.82%
BALYASNY ASSET MANAGEMENT L.P.4.96%
a16z Capital Management, L.L.C.4.09%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.78%
Trails Edge Capital Partners, LP3.72%
BlackRock, Inc.3.17%
VANGUARD CAPITAL MANAGEMENT LLC2.95%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.19%
Select Biotechnology Portfolio2.11%
iShares Russell 2000 ETF0.87%
VANGUARD EXTENDED MARKET INDEX FUND0.69%
Fidelity Growth Company Fund0.67%
Fidelity Small Cap Index Fund0.66%
iShares Russell 2000 Growth ETF0.52%
Victory Science & Technology Fund0.44%
VANGUARD RUSSELL 2000 INDEX FUND0.29%
Fidelity Extended Market Index Fund0.25%

OakChart. CAMP. Cached 15 minutes.